Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 668

1.
3.

Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.

Motosugi U, Ichikawa T, Sou H, Sano K, Tominaga L, Muhi A, Araki T.

Radiology. 2010 Jul;256(1):151-8. doi: 10.1148/radiol.10091885.

PMID:
20574092
4.
5.
6.

Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging.

Yu MH, Kim JH, Yoon JH, Kim HC, Chung JW, Han JK, Choi BI.

Radiology. 2014 Jun;271(3):748-60. doi: 10.1148/radiol.14131996. Epub 2014 Feb 1.

PMID:
24588677
7.
8.
9.

Detection of hepatocellular carcinoma in gadoxetic acid-enhanced MRI and diffusion-weighted MRI with respect to the severity of liver cirrhosis.

Kim AY, Kim YK, Lee MW, Park MJ, Hwang J, Lee MH, Lee JW.

Acta Radiol. 2012 Oct 1;53(8):830-8. doi: 10.1258/ar.2012.120099. Epub 2012 Jul 30.

PMID:
22847903
10.

Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients.

Phongkitkarun S, Limsamutpetch K, Tannaphai P, Jatchavala J.

World J Gastroenterol. 2013 Dec 7;19(45):8357-65. doi: 10.3748/wjg.v19.i45.8357.

11.

Newly developed hypervascular hepatocellular carcinoma during follow-up periods in patients with chronic liver disease: observation in serial gadoxetic acid-enhanced MRI.

Yamamoto A, Ito K, Tamada T, Higaki A, Kanki A, Sato T, Tanimoto D.

AJR Am J Roentgenol. 2013 Jun;200(6):1254-60. doi: 10.2214/AJR.12.9136.

PMID:
23701061
12.

Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.

Sun HY, Lee JM, Shin CI, Lee DH, Moon SK, Kim KW, Han JK, Choi BI.

Invest Radiol. 2010 Feb;45(2):96-103. doi: 10.1097/RLI.0b013e3181c5faf7.

PMID:
20057319
13.

Hepatocellular carcinoma in North America: a multiinstitutional study of appearance on T1-weighted, T2-weighted, and serial gadolinium-enhanced gradient-echo images.

Kelekis NL, Semelka RC, Worawattanakul S, de Lange EE, Ascher SM, Ahn IO, Reinhold C, Remer EM, Brown JJ, Bis KG, Woosley JT, Mitchell DG.

AJR Am J Roentgenol. 1998 Apr;170(4):1005-13.

PMID:
9530051
14.

Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI.

Chong YS, Kim YK, Lee MW, Kim SH, Lee WJ, Rhim HC, Lee SJ.

Clin Radiol. 2012 Aug;67(8):766-73. doi: 10.1016/j.crad.2012.01.004. Epub 2012 Mar 15.

PMID:
22425613
15.

Detection of small hepatocellular carcinoma using gadoxetic acid-enhanced MRI: Is the addition of diffusion-weighted MRI at 3.0T beneficial?

Zhao XT, Li WX, Chai WM, Chen KM.

J Dig Dis. 2014 Mar;15(3):137-45. doi: 10.1111/1751-2980.12119.

PMID:
24354621
16.

Detection of liver malignancy with gadoxetic acid-enhanced MRI: is addition of diffusion-weighted MRI beneficial?

Kim YK, Kim CS, Han YM, Lee YH.

Clin Radiol. 2011 Jun;66(6):489-96. doi: 10.1016/j.crad.2010.09.007. Epub 2011 Mar 1. Erratum in: Clin Radiol. 2011 Oct;66(10):1006.

PMID:
21367403
17.

Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma.

Hyodo T, Murakami T, Imai Y, Okada M, Hori M, Kagawa Y, Kogita S, Kumano S, Kudo M, Mochizuki T.

Radiology. 2013 Feb;266(2):480-90. doi: 10.1148/radiol.12112677.

PMID:
23362095
18.
19.

Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker.

Choi JW, Lee JM, Kim SJ, Yoon JH, Baek JH, Han JK, Choi BI.

Radiology. 2013 Jun;267(3):776-86. doi: 10.1148/radiol.13120775. Epub 2013 Feb 11.

PMID:
23401584
20.

Small hypervascular hepatocellular carcinoma: limited value of portal and delayed phases on dynamic magnetic resonance imaging.

Yu JS, Lee JH, Chung JJ, Kim JH, Kim KW.

Acta Radiol. 2008 Sep;49(7):735-43. doi: 10.1080/02841850802120045.

PMID:
18608015

Supplemental Content

Support Center